Summary & Overview
CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcript Testing
CPT code 0016U designates a proprietary molecular diagnostic assay for detection and characterization of BCR–ABL1 major and minor breakpoint fusion transcripts performed by the University of Iowa, Department of Pathology or Asuragen on whole blood or bone marrow aspiration specimens. This PLA code matters nationally because BCR–ABL1 testing directly informs diagnosis, treatment selection, and monitoring for patients with BCR–ABL1–positive leukemias, where molecular results impact targeted therapy decisions and disease surveillance.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical and laboratory context, payer coverage considerations, common billing modifiers, and the typical service setting. The publication outlines benchmark elements and policy-relevant details that affect national coverage and billing for proprietary laboratory assays, including how PLA codes like 0016U are used to represent manufacturer- or lab-specific tests. The content highlights operational implications for laboratories and billing teams, and provides clarity on where this code fits within molecular diagnostic service lines.
This summary is intended for a national audience of clinicians, laboratory directors, and revenue cycle professionals seeking a clear, policy-oriented briefing on CPT code 0016U.
Billing Code Overview
CPT code 0016U is a Proprietary Laboratory Analyses (PLA) code describing BCR–ABL1 major and minor breakpoint fusion transcript testing performed by the University of Iowa, Department of Pathology or Asuragen on whole blood or bone marrow aspiration specimens. The test identifies and characterizes BCR–ABL1 fusion transcript variants (major and minor breakpoints) used in the molecular diagnosis and monitoring of BCR–ABL1–positive hematologic neoplasms.
Service type: Proprietary molecular diagnostic laboratory test
Typical site of service: Clinical laboratory or hospital laboratory
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with newly diagnosed chronic myeloid leukemia (CML) presents for initial molecular baseline testing and later for routine disease monitoring. Peripheral whole blood or bone marrow aspiration is collected and sent to a reference laboratory (University of Iowa Department of Pathology or Asuragen) for BCR–ABL1 major (p210) and minor (p190) breakpoint fusion transcript quantification using a validated laboratory-developed test described by PLA code 0016U. The clinical workflow includes: ordering the test in the electronic medical record, obtaining informed consent for laboratory testing as required by the facility, phlebotomy or bone marrow aspiration by oncology or hematology staff, specimen packaging and shipment to the performing lab, and receipt of a quantitative molecular report used by the treating hematologist/oncologist to guide diagnosis, initial therapy selection, and ongoing response assessment (to assess molecular response, minimal residual disease, or possible relapse). Typical sites of service are hospital inpatient, hospital outpatient infusion or oncology clinic, and reference laboratory processing. Common clinical indications include initial confirmation of BCR–ABL1 transcript presence at diagnosis, baseline quantification before tyrosine kinase inhibitor therapy, periodic monitoring for major molecular response, and evaluation of rising transcript levels suggesting loss of response or resistance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Service or procedure provided without a bilateral, multiple, or repeated procedure indicator | Rarely used; not typically applied to lab PLA codes but present in modifier list |
11 | Standard services | Use when the test is performed as the routine, non-altered service |
22 | Increased procedural services | Use when additional complexity or time beyond typical laboratory processing is documented (rare for PLA) |
26 | Professional component | Use when billing is split and the professional component (interpretation/medical review) is billed separately from technical component |
52 | Reduced services | Use if the performing lab documents that the full test procedure could not be completed and a reduced service was provided |
53 | Discontinued procedure | Use if specimen collection or processing was started but discontinued for valid clinical reasons |
62 | Two surgeons or physicians | Not commonly applied to lab tests; used only if two qualified providers share responsibility for interpretation |
78 | Unplanned return to the operating/procedure room | Not applicable to standard lab testing; not typically used |
80 | Assistant surgeon | Not applicable to this lab service |
AD | Senior clinician performing service in training settings | Use when a designated senior practitioner assumes primary responsibility for the interpretation in teaching settings |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 2080P0800X | Hematology | Hematologists commonly order and interpret BCR–ABL1 testing |
| 207LN0000X | Hematopathology | Hematopathologists often perform or oversee molecular diagnostic testing and result interpretation |
| 207Q00000X | Medical Oncology | Medical oncologists manage CML therapy and use results for treatment decisions |
| 207L00000X | Pathology | Pathologists may be involved when testing is sent through hospital pathology departments |
| 2084P0800X | Laboratory Medicine | Laboratory medicine specialists oversee test validation, quality, and reporting |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
C92.1 | Chronic myelogenous leukemia (CML) | Primary diagnosis for which BCR–ABL1 major breakpoint testing is ordered for diagnosis and monitoring |
C92.0 | Acute myelogenous leukemia (AML) | Molecular testing may be used when variant transcripts are suspected or for differential diagnosis |
C93.1 | Chronic myelomonocytic leukemia | Molecular assays can assist in distinguishing myeloid neoplasms when clinical features overlap |
D47.1 | Chronic myeloproliferative disease | Testing may be used during evaluation for specific BCR–ABL1–positive disorders |
R79.89 | Other specified abnormal findings of blood chemistry | Abnormal laboratory findings prompting further molecular evaluation |
Z51.11 | Encounter for antineoplastic chemotherapy | Monitoring BCR–ABL1 transcript levels during therapy to assess response |
Z08 | Encounter for follow-up examination after completed treatment for malignant neoplasm | Post-treatment surveillance using molecular monitoring |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
81025 | Urinalysis, by dip stick or tablet reagent; multiple constituents, non-automated, with microscopy | Often performed as part of baseline evaluation but not directly related to molecular testing |
36415 | Collection of venous blood by venipuncture | Commonly performed to obtain peripheral whole blood specimen sent for 0016U |
38221 | Bone marrow; aspiration only | Performed when bone marrow aspiration is required for specimen collection for BCR–ABL1 testing |
86336 | BCR-ABL p210 (This is an example molecular immunoassay code) | Other molecular tests for BCR-ABL may be ordered alongside or instead of the PLA; used in parallel workflows |
88363 | Flow cytometry test(s) performed using peripheral blood or bone marrow aspirate; interpretation and report | Performed in hematologic malignancy workups and may accompany molecular testing for comprehensive assessment |